DE122008000043I1 - Neurotoxisches Komponente von Botulinumtoxinen zur Behandlung von zervikaler Dystonie - Google Patents
Neurotoxisches Komponente von Botulinumtoxinen zur Behandlung von zervikaler DystonieInfo
- Publication number
- DE122008000043I1 DE122008000043I1 DE122008000043C DE122008000043C DE122008000043I1 DE 122008000043 I1 DE122008000043 I1 DE 122008000043I1 DE 122008000043 C DE122008000043 C DE 122008000043C DE 122008000043 C DE122008000043 C DE 122008000043C DE 122008000043 I1 DE122008000043 I1 DE 122008000043I1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- botulinum toxins
- cervical dystonia
- neurotoxic component
- neurotoxic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17399693A | 1993-12-28 | 1993-12-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE122008000043I1 true DE122008000043I1 (de) | 2008-11-20 |
Family
ID=22634387
Family Applications (23)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69435270T Expired - Lifetime DE69435270D1 (de) | 1993-12-28 | 1994-12-16 | Verwendung der neurotoxischen Komponente von Botulinum Toxin zur Behandlung spastischer Muskeln |
DE69434319T Expired - Lifetime DE69434319T3 (de) | 1993-12-28 | 1994-12-16 | Botulinustoxine A oder B zur Behandlung von Schmerzen verbunden mit Glattmuskelkrämpfen |
DE122008000043C Pending DE122008000043I1 (de) | 1993-12-28 | 1994-12-16 | Neurotoxisches Komponente von Botulinumtoxinen zur Behandlung von zervikaler Dystonie |
DE69434535T Revoked DE69434535T2 (de) | 1993-12-28 | 1994-12-16 | Toxische Komponente der Botulinumtoxine zur Modulation cholinergisch kontrollierter Sekretionen |
DE69434443T Revoked DE69434443T2 (de) | 1993-12-28 | 1994-12-16 | Verwendung der neutrotoxischen Komponente des Botulinum Toxins zur Muskelschmerzbehandlung |
DE122009000038C Pending DE122009000038I1 (de) | 1993-12-28 | 1994-12-16 | Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Reduzierung von Schmerzen bedingt durch Muskelkrankheit |
DE69435243T Expired - Lifetime DE69435243D1 (de) | 1993-12-28 | 1994-12-16 | Verwendung vom neurotoxischem Komponent von Botulinum Toxin zur Behandlung von Glattmuskelkrankheiten |
DE69435302T Expired - Lifetime DE69435302D1 (de) | 1993-12-28 | 1994-12-16 | Neurotoxisches Komponent eines Botulinumtoxins zur Behandlung von Spätdyskinesie |
DE69435321T Expired - Lifetime DE69435321D1 (de) | 1993-12-28 | 1994-12-16 | Verwendung von Botulinum Toxin zur Behandlung des myofascialen Schmerzsyndroms |
DE69434540T Expired - Lifetime DE69434540T2 (de) | 1993-12-28 | 1994-12-16 | Neurotoxisches Komponente von Botulinumtoxinen zur Behandlung von zervikaler Dystonie |
DE69428813T Expired - Lifetime DE69428813T2 (de) | 1993-12-28 | 1994-12-16 | Verwendung von Botulinustoxin zur Behandlung von Spannungs-Kopfschmerz |
DE69435116T Expired - Lifetime DE69435116D1 (de) | 1993-12-28 | 1994-12-16 | Verwendung von Botulinumtoxin für die Herstellung eines Arzneimittels zur Linderung von Rückenschmerzen |
DE69435249T Expired - Lifetime DE69435249D1 (de) | 1993-12-28 | 1994-12-16 | Verwendung vom neurotoxischem Komponent von Botulinum toxin zur Behandlung von einem spastischem Muskel |
DE69435276T Expired - Lifetime DE69435276D1 (de) | 1993-12-28 | 1994-12-16 | Verwendung vom neurotoxischen Komponent der Botulinum Toxin zur Muskelschmerzbehandlung bei cervikaler Dystonie |
DE69435149T Expired - Lifetime DE69435149D1 (de) | 1993-12-28 | 1994-12-16 | Verwendung von Botulinum Toxine gegen Schwitzen bei Menschen |
DE69434511T Expired - Lifetime DE69434511T2 (de) | 1993-12-28 | 1994-12-16 | Botulinumtoxin zur Behandlung von Dystonie |
DE69435194T Expired - Lifetime DE69435194D1 (de) | 1993-12-28 | 1994-12-16 | Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Reduzierung von Schmerzen bedingt durch Muskelkrankheit |
DE122008000042C Pending DE122008000042I1 (de) | 1993-12-28 | 1994-12-16 | Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen |
DE69433394T Expired - Lifetime DE69433394T3 (de) | 1993-12-28 | 1994-12-16 | Botulinustoxine zur Modulation cholinergisch-kontrollierter Sekretionen |
DE69435330T Expired - Lifetime DE69435330D1 (de) | 1993-12-28 | 1994-12-16 | Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen |
DE69434008T Expired - Lifetime DE69434008T2 (de) | 1993-12-28 | 1994-12-16 | Botulinumtoxin zur Behandlung von mit Muskelkrankheiten verbundenen Schmerzen |
DE69434610T Expired - Lifetime DE69434610T2 (de) | 1993-12-28 | 1994-12-16 | Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen |
DE69427869T Expired - Lifetime DE69427869T2 (de) | 1993-12-28 | 1994-12-16 | Botulinumtoxine zur behandlung von hyperhydrosis |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69435270T Expired - Lifetime DE69435270D1 (de) | 1993-12-28 | 1994-12-16 | Verwendung der neurotoxischen Komponente von Botulinum Toxin zur Behandlung spastischer Muskeln |
DE69434319T Expired - Lifetime DE69434319T3 (de) | 1993-12-28 | 1994-12-16 | Botulinustoxine A oder B zur Behandlung von Schmerzen verbunden mit Glattmuskelkrämpfen |
Family Applications After (20)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69434535T Revoked DE69434535T2 (de) | 1993-12-28 | 1994-12-16 | Toxische Komponente der Botulinumtoxine zur Modulation cholinergisch kontrollierter Sekretionen |
DE69434443T Revoked DE69434443T2 (de) | 1993-12-28 | 1994-12-16 | Verwendung der neutrotoxischen Komponente des Botulinum Toxins zur Muskelschmerzbehandlung |
DE122009000038C Pending DE122009000038I1 (de) | 1993-12-28 | 1994-12-16 | Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Reduzierung von Schmerzen bedingt durch Muskelkrankheit |
DE69435243T Expired - Lifetime DE69435243D1 (de) | 1993-12-28 | 1994-12-16 | Verwendung vom neurotoxischem Komponent von Botulinum Toxin zur Behandlung von Glattmuskelkrankheiten |
DE69435302T Expired - Lifetime DE69435302D1 (de) | 1993-12-28 | 1994-12-16 | Neurotoxisches Komponent eines Botulinumtoxins zur Behandlung von Spätdyskinesie |
DE69435321T Expired - Lifetime DE69435321D1 (de) | 1993-12-28 | 1994-12-16 | Verwendung von Botulinum Toxin zur Behandlung des myofascialen Schmerzsyndroms |
DE69434540T Expired - Lifetime DE69434540T2 (de) | 1993-12-28 | 1994-12-16 | Neurotoxisches Komponente von Botulinumtoxinen zur Behandlung von zervikaler Dystonie |
DE69428813T Expired - Lifetime DE69428813T2 (de) | 1993-12-28 | 1994-12-16 | Verwendung von Botulinustoxin zur Behandlung von Spannungs-Kopfschmerz |
DE69435116T Expired - Lifetime DE69435116D1 (de) | 1993-12-28 | 1994-12-16 | Verwendung von Botulinumtoxin für die Herstellung eines Arzneimittels zur Linderung von Rückenschmerzen |
DE69435249T Expired - Lifetime DE69435249D1 (de) | 1993-12-28 | 1994-12-16 | Verwendung vom neurotoxischem Komponent von Botulinum toxin zur Behandlung von einem spastischem Muskel |
DE69435276T Expired - Lifetime DE69435276D1 (de) | 1993-12-28 | 1994-12-16 | Verwendung vom neurotoxischen Komponent der Botulinum Toxin zur Muskelschmerzbehandlung bei cervikaler Dystonie |
DE69435149T Expired - Lifetime DE69435149D1 (de) | 1993-12-28 | 1994-12-16 | Verwendung von Botulinum Toxine gegen Schwitzen bei Menschen |
DE69434511T Expired - Lifetime DE69434511T2 (de) | 1993-12-28 | 1994-12-16 | Botulinumtoxin zur Behandlung von Dystonie |
DE69435194T Expired - Lifetime DE69435194D1 (de) | 1993-12-28 | 1994-12-16 | Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Reduzierung von Schmerzen bedingt durch Muskelkrankheit |
DE122008000042C Pending DE122008000042I1 (de) | 1993-12-28 | 1994-12-16 | Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen |
DE69433394T Expired - Lifetime DE69433394T3 (de) | 1993-12-28 | 1994-12-16 | Botulinustoxine zur Modulation cholinergisch-kontrollierter Sekretionen |
DE69435330T Expired - Lifetime DE69435330D1 (de) | 1993-12-28 | 1994-12-16 | Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen |
DE69434008T Expired - Lifetime DE69434008T2 (de) | 1993-12-28 | 1994-12-16 | Botulinumtoxin zur Behandlung von mit Muskelkrankheiten verbundenen Schmerzen |
DE69434610T Expired - Lifetime DE69434610T2 (de) | 1993-12-28 | 1994-12-16 | Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen |
DE69427869T Expired - Lifetime DE69427869T2 (de) | 1993-12-28 | 1994-12-16 | Botulinumtoxine zur behandlung von hyperhydrosis |
Country Status (9)
Country | Link |
---|---|
EP (23) | EP1602379A1 (de) |
JP (33) | JP3238154B2 (de) |
AU (1) | AU688452B2 (de) |
CA (2) | CA2682117A1 (de) |
DE (23) | DE69435270D1 (de) |
ES (18) | ES2207910T5 (de) |
FR (1) | FR08C0034I1 (de) |
HK (6) | HK1033274A1 (de) |
WO (1) | WO1995017904A2 (de) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9120306D0 (en) | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
JPH08511536A (ja) | 1993-06-10 | 1996-12-03 | アラーガン、インコーポレイテッド | 複数の血清型のボツリヌス毒素により、神経筋疾患および症状を処置する方法 |
DE69435270D1 (de) * | 1993-12-28 | 2010-04-01 | Allergan Inc | Verwendung der neurotoxischen Komponente von Botulinum Toxin zur Behandlung spastischer Muskeln |
AU2007202480B2 (en) * | 1993-12-28 | 2009-01-29 | Allergan, Inc. | Method for treating pain associated with a muscle disorder |
US8557256B2 (en) | 1993-12-28 | 2013-10-15 | Allergan, Inc. | Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin |
US8187612B2 (en) | 1993-12-28 | 2012-05-29 | Allergan, Inc. | Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle |
US6974578B1 (en) * | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
ES2238969T3 (es) * | 1994-05-09 | 2005-09-16 | William J. Binder | Neurotoxinas presinapticas para el tratamiento de cefaleas migrañosas. |
US5721215A (en) * | 1996-03-20 | 1998-02-24 | Allergan | Injectable therapy for control of muscle spasms and pain related to muscle spasms |
US6699966B1 (en) | 1996-07-08 | 2004-03-02 | University Of Massachusetts | Proteins within the type E botulinum neurotoxin complex |
US6780413B2 (en) | 1996-09-19 | 2004-08-24 | The United States Of America As Represented By The Department Of Health And Human Services | Immunotoxin (mAB-RICIN) for the treatment of focal movement disorders |
AU2008201535C1 (en) * | 1997-07-15 | 2013-09-12 | Allergan, Inc. | Use of neurotoxin therapy for treatment of urologic and related disorders |
AU2006225233C1 (en) * | 1997-07-15 | 2011-02-10 | Allergan, Inc. | Use of neurotoxin therapy for treatment of urologic and related disorders |
US7455845B2 (en) | 1997-07-15 | 2008-11-25 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure |
US7470431B2 (en) | 1997-07-15 | 2008-12-30 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer |
US7449192B2 (en) | 1997-07-15 | 2008-11-11 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction |
US9066943B2 (en) | 1997-07-15 | 2015-06-30 | The Regents Of The University Of Colorado | Use of botulinum toxin therapy for treatment of urological neurological conditions |
ES2385130T3 (es) | 1997-07-15 | 2012-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Uso de terapia con neurotoxinas para el tratamiento de enfermedades urológicas y de enfermedades relacionadas |
US6063768A (en) * | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
AU2340299A (en) | 1998-01-26 | 1999-08-09 | University Of Massachusetts | Biologically active hemagglutinin from type a (clostridium botulinum) and methods of use |
US8790897B2 (en) | 1998-08-25 | 2014-07-29 | Syntaxin Ltd. | Treatment of mucus hypersecretion |
GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
US20040071736A1 (en) | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
TW574036B (en) | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
DE19856897A1 (de) * | 1998-12-10 | 2000-06-15 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum zur Unterdrückung von Schnarchgeräuschen |
DE19925739A1 (de) | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
US6767544B2 (en) * | 2002-04-01 | 2004-07-27 | Allergan, Inc. | Methods for treating cardiovascular diseases with botulinum toxin |
US6977080B1 (en) * | 1999-08-10 | 2005-12-20 | Allergan, Inc. | Intrapericardial botulinum toxin treatment for bradycardia |
GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
US6139845A (en) * | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
US6261572B1 (en) * | 2000-01-11 | 2001-07-17 | Allergan Sales, Inc. | Method for treating a pancreatic disorder with a neurotoxin |
US6143306A (en) * | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
US6337075B1 (en) | 2000-01-11 | 2002-01-08 | Allergan Sales, Inc. | Methods for treating diabetes |
US6358513B1 (en) * | 2000-02-15 | 2002-03-19 | Allergan Sales, Inc. | Method for treating Hashimoto's thyroiditis |
US6524580B1 (en) * | 2000-02-15 | 2003-02-25 | Allergan Sales, Inc. | Method for treating thyroid disorders |
US6328977B1 (en) * | 2000-02-22 | 2001-12-11 | Allergan Sales, Inc. | Method for treating hyperparathyroidism |
US6464986B1 (en) * | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
US6565870B1 (en) | 2000-04-28 | 2003-05-20 | Allergan, Inc. | Methods for treating bone tumors |
US6306403B1 (en) * | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
WO2002009743A1 (en) * | 2000-08-02 | 2002-02-07 | Allergan Sales, Inc. | Method for treating a neoplasm |
US6423319B1 (en) | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
US6827931B1 (en) | 2000-10-20 | 2004-12-07 | Allergan, Inc. | Method for treating endocrine disorders |
US20020086036A1 (en) | 2000-12-05 | 2002-07-04 | Allergan Sales, Inc. | Methods for treating hyperhidrosis |
US7255865B2 (en) | 2000-12-05 | 2007-08-14 | Allergan, Inc. | Methods of administering botulinum toxin |
ITUD20010002A1 (it) | 2001-01-05 | 2002-07-05 | Univ Degli Studi Udine | Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo |
GB0111146D0 (en) * | 2001-05-04 | 2001-06-27 | Imp College Innovations Ltd | Methods |
JP2003009897A (ja) | 2001-07-03 | 2003-01-14 | Keiji Oguma | ボツリヌス毒素の分離・精製法 |
KR20030018827A (ko) * | 2001-08-31 | 2003-03-06 | 서구일 | A형 보툴리눔 독소를 유효성분으로 포함하는 신경차단제,및 이를 이용한 교감신경절 차단의 적응질환 치료제 |
US7255866B2 (en) | 2001-09-17 | 2007-08-14 | Allergan, Inc. | Botulinum toxin therapy for fibromyalgia |
US6623742B2 (en) | 2001-09-17 | 2003-09-23 | Allergan, Inc. | Methods for treating fibromyalgia |
US20030113349A1 (en) | 2001-12-18 | 2003-06-19 | Coleman William P. | Topically applied clostridium botulinum toxin compositions and treatment methods |
US6921538B2 (en) * | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
US6776991B2 (en) | 2002-06-26 | 2004-08-17 | Allergan, Inc. | Methods for treating priapism |
US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
KR20050061541A (ko) * | 2002-10-15 | 2005-06-22 | 알러간, 인코포레이티드 | 보툴리눔 독소 치과 치료 및 시술 |
US20040086532A1 (en) | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
US7238357B2 (en) | 2002-11-05 | 2007-07-03 | Allergan, Inc. | Methods for treating ulcers and gastroesophageal reflux disease |
MXPA05009425A (es) * | 2003-03-06 | 2006-02-10 | Botulinum Toxin Res Ass Inc | Tratamiento del dolor facial cronico y cefalea relacionados con la sinusitis con toxina botulinica. |
MXPA05009424A (es) | 2003-03-06 | 2006-02-10 | Botulinum Toxin Res Ass Inc | Tratamiento de chalazion cronico y hordeolum con la toxina botulinica. |
US7220422B2 (en) * | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
FR2857595B1 (fr) * | 2003-07-18 | 2005-10-07 | Sod Conseils Rech Applic | Utilisation de toxine botulique pour preparer un medicament destine a prevenir ou traiter les troubles sonores lies a l'agonie |
US8609112B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
US8734810B2 (en) | 2003-10-29 | 2014-05-27 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
US8609113B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
US8617572B2 (en) | 2003-10-29 | 2013-12-31 | Allergan, Inc. | Botulinum toxin treatments of depression |
US7276244B2 (en) | 2004-02-12 | 2007-10-02 | Philip Radovic | Methods of treating abnormalities of the first metatarsophalangeal joint of the foot |
CA2555939A1 (en) * | 2004-02-12 | 2005-09-01 | Philip Radovic | Treatment of abnormalities of the first metatarsophalangeal joint of the foot |
US20050191321A1 (en) * | 2004-02-26 | 2005-09-01 | Allergan, Inc. | Methods for treating headache |
CA3031270A1 (en) | 2004-03-03 | 2005-12-22 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
EP1729821B1 (de) | 2004-03-03 | 2013-07-17 | ReVance Therapeutics, Inc. | Zusammensetzungen und methoden zur topischen anwendung und transdermalen verabreichung von botulinus toxinen |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
EP1861112A4 (de) | 2005-03-03 | 2009-07-22 | Revance Therapeutics Inc | Zusammensetzungen und verfahren zur topischen anwendung und transdermalen abgabe von botulinumtoxinen |
EP1747782A1 (de) | 2005-07-19 | 2007-01-31 | Cesare Montecucco | Produkte zur topischen Anwendung enthaltend Lysophospholipide und Fettsäuren |
US7910116B2 (en) | 2005-08-24 | 2011-03-22 | Allergan, Inc. | Use of a botulinum toxin to improve gastric emptying and/or to treat GERD |
CN101355962A (zh) | 2005-11-17 | 2009-01-28 | 雷文斯治疗公司 | 减少非毒素蛋白质的肉毒杆菌毒素组合物和其局部施用及透皮递送方法 |
US7655625B2 (en) | 2006-02-13 | 2010-02-02 | Allergan, Inc. | Methods of treating blepharospasm using cyclosporine components |
US7794386B2 (en) | 2006-03-15 | 2010-09-14 | Allergan, Inc. | Methods for facilitating weight loss |
US7811586B2 (en) | 2006-05-02 | 2010-10-12 | Allergan, Inc. | Methods for alleviating testicular pain |
FR2902341B1 (fr) | 2006-06-16 | 2011-02-25 | Scras | Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace |
AR061669A1 (es) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
US10792344B2 (en) | 2006-06-29 | 2020-10-06 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of botulinum toxin therapy |
FR2907680B1 (fr) | 2006-10-27 | 2012-12-28 | Scras | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux |
FR2910327B1 (fr) | 2006-12-22 | 2013-04-26 | Scras | Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida. |
WO2008121067A1 (en) | 2007-03-30 | 2008-10-09 | Anders Fagergren | Quantification of mechanical and neural contributions to spasticity |
EP2178549B1 (de) | 2007-07-26 | 2016-09-14 | Revance Therapeutics, Inc. | Antimikrobielles peptid und deren zusammensetzungen |
EP2072039A1 (de) * | 2007-12-21 | 2009-06-24 | Merz Pharma GmbH & Co.KGaA | Verwendung eines neurotoxischen Bestandteils des Clostridium-botulinum-Toxinkomplexes zur Verringerung oder Verhütung von Nebenwirkungen |
US8470337B2 (en) | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
FR2930447B1 (fr) | 2008-04-25 | 2010-07-30 | Sod Conseils Rech Applic | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique |
US20100124559A1 (en) * | 2008-11-20 | 2010-05-20 | Allergan, Inc. | Early Treatment and Prevention of Increased Muscle Tonicity |
DK3332805T3 (da) | 2008-12-31 | 2022-05-16 | Revance Therapeutics Inc | Injicerbare botulinumtoksinformuleringer |
BRPI1015938A2 (pt) | 2009-06-25 | 2016-09-27 | Revance Therapeutics Inc | formulações da toxina botulínica livre de albumina |
US8147848B2 (en) | 2009-08-26 | 2012-04-03 | Allergan, Inc. | Method for treating premature ejaculation with a botulinum neurotoxin |
US20140120077A1 (en) | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and Methods for Safe Treatment of Rhinitis |
RU2545453C2 (ru) * | 2013-03-21 | 2015-03-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ лечения переломов нижней челюсти |
US10149893B2 (en) | 2013-09-24 | 2018-12-11 | Allergan, Inc. | Methods for modifying progression of osteoarthritis |
KR101677710B1 (ko) * | 2014-06-30 | 2016-11-21 | (주)메디톡스 | 보툴리눔 독소를 유효성분으로 포함하는 골관절염 치료용 약제학적 조성물 및 그를 이용한 골관절염 치료 방법 |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
KR20240023684A (ko) * | 2016-09-13 | 2024-02-22 | 알레간 인코포레이티드 | 안정화된 비단백질 클로스트리듐 독소 조성물 |
WO2020047159A1 (en) * | 2018-08-28 | 2020-03-05 | Ira Sanders | Skin therapeutics |
RU2732204C1 (ru) * | 2020-01-28 | 2020-09-14 | Частное учреждение образовательная организация высшего образования "Медицинский университет "Реавиз" | Способ лечения головных болей напряжения по Гурову-Левину |
CN116348480A (zh) * | 2020-10-07 | 2023-06-27 | 普罗塔克斯公司 | 肉毒杆菌毒素的真空干燥方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4362731A (en) * | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
US4664911A (en) | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
US5053005A (en) | 1989-04-21 | 1991-10-01 | Gary E. Borodic | Chemomodulation of curvature of the juvenile spine |
GB9022250D0 (en) * | 1990-10-12 | 1990-11-28 | Glaxo Group Ltd | Medicaments |
GB9120306D0 (en) * | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
AU4646393A (en) * | 1992-06-23 | 1994-01-24 | Interactive Biologics Associates | Pharmaceutical composition containing botulinum b complex |
JP4381477B2 (ja) * | 1993-01-15 | 2009-12-09 | ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド | 筋膜疼痛症候群の治療方法 |
JPH08511536A (ja) * | 1993-06-10 | 1996-12-03 | アラーガン、インコーポレイテッド | 複数の血清型のボツリヌス毒素により、神経筋疾患および症状を処置する方法 |
JP4249802B2 (ja) * | 1993-06-10 | 2009-04-08 | アラーガン、インコーポレイテッド | 神経筋疾患および症状を処置するためのボツリヌス毒素組み合わせ |
US5437291A (en) * | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
DE69435270D1 (de) * | 1993-12-28 | 2010-04-01 | Allergan Inc | Verwendung der neurotoxischen Komponente von Botulinum Toxin zur Behandlung spastischer Muskeln |
US5766605A (en) * | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
ES2238969T3 (es) * | 1994-05-09 | 2005-09-16 | William J. Binder | Neurotoxinas presinapticas para el tratamiento de cefaleas migrañosas. |
JP2001104991A (ja) * | 1999-10-12 | 2001-04-17 | Toyoaki Kubota | 循環水の有機質除去剤 |
-
1994
- 1994-12-16 DE DE69435270T patent/DE69435270D1/de not_active Expired - Lifetime
- 1994-12-16 DE DE69434319T patent/DE69434319T3/de not_active Expired - Lifetime
- 1994-12-16 ES ES99203920T patent/ES2207910T5/es not_active Expired - Lifetime
- 1994-12-16 EP EP05017284A patent/EP1602379A1/de not_active Withdrawn
- 1994-12-16 ES ES05016177T patent/ES2340172T3/es not_active Expired - Lifetime
- 1994-12-16 DE DE122008000043C patent/DE122008000043I1/de active Pending
- 1994-12-16 EP EP01118792A patent/EP1147775B1/de not_active Expired - Lifetime
- 1994-12-16 EP EP04019048A patent/EP1488803B1/de not_active Revoked
- 1994-12-16 EP EP04019047A patent/EP1477183B1/de not_active Revoked
- 1994-12-16 DE DE69434535T patent/DE69434535T2/de not_active Revoked
- 1994-12-16 ES ES07002714T patent/ES2309973T3/es not_active Expired - Lifetime
- 1994-12-16 DE DE69434443T patent/DE69434443T2/de not_active Revoked
- 1994-12-16 DE DE122009000038C patent/DE122009000038I1/de active Pending
- 1994-12-16 EP EP08017803A patent/EP2027872B1/de not_active Expired - Lifetime
- 1994-12-16 DE DE69435243T patent/DE69435243D1/de not_active Expired - Lifetime
- 1994-12-16 DE DE69435302T patent/DE69435302D1/de not_active Expired - Lifetime
- 1994-12-16 EP EP06016208A patent/EP1757325B1/de not_active Expired - Lifetime
- 1994-12-16 DE DE69435321T patent/DE69435321D1/de not_active Expired - Lifetime
- 1994-12-16 EP EP04000166A patent/EP1421948B1/de not_active Expired - Lifetime
- 1994-12-16 ES ES97200028T patent/ES2163090T3/es not_active Expired - Lifetime
- 1994-12-16 ES ES03015590T patent/ES2251651T3/es not_active Expired - Lifetime
- 1994-12-16 EP EP01118793A patent/EP1147776B1/de not_active Expired - Lifetime
- 1994-12-16 EP EP03015589A patent/EP1366770B1/de not_active Revoked
- 1994-12-16 EP EP00203294A patent/EP1072270B1/de not_active Expired - Lifetime
- 1994-12-16 ES ES95906674T patent/ES2159624T3/es not_active Expired - Lifetime
- 1994-12-16 EP EP04018914A patent/EP1486214A1/de not_active Withdrawn
- 1994-12-16 CA CA002682117A patent/CA2682117A1/en not_active Abandoned
- 1994-12-16 DE DE69434540T patent/DE69434540T2/de not_active Expired - Lifetime
- 1994-12-16 EP EP95906674A patent/EP0737074B1/de not_active Expired - Lifetime
- 1994-12-16 ES ES01118793T patent/ES2355491T3/es not_active Expired - Lifetime
- 1994-12-16 DE DE69428813T patent/DE69428813T2/de not_active Expired - Lifetime
- 1994-12-16 EP EP05006665.3A patent/EP1563843B1/de not_active Expired - Lifetime
- 1994-12-16 EP EP04019046A patent/EP1502600B1/de not_active Expired - Lifetime
- 1994-12-16 DE DE69435116T patent/DE69435116D1/de not_active Expired - Lifetime
- 1994-12-16 DE DE69435249T patent/DE69435249D1/de not_active Expired - Lifetime
- 1994-12-16 ES ES00203294T patent/ES2246800T3/es not_active Expired - Lifetime
- 1994-12-16 EP EP97200028A patent/EP0770395B1/de not_active Expired - Lifetime
- 1994-12-16 EP EP05016177A patent/EP1591129B1/de not_active Expired - Lifetime
- 1994-12-16 AU AU15162/95A patent/AU688452B2/en not_active Ceased
- 1994-12-16 CA CA002180011A patent/CA2180011C/en not_active Expired - Lifetime
- 1994-12-16 EP EP99203920A patent/EP1005867B2/de not_active Expired - Lifetime
- 1994-12-16 DE DE69435276T patent/DE69435276D1/de not_active Expired - Lifetime
- 1994-12-16 DE DE69435149T patent/DE69435149D1/de not_active Expired - Lifetime
- 1994-12-16 EP EP05018367A patent/EP1600163B1/de not_active Expired - Lifetime
- 1994-12-16 ES ES04019048T patent/ES2248780T3/es not_active Expired - Lifetime
- 1994-12-16 DE DE69434511T patent/DE69434511T2/de not_active Expired - Lifetime
- 1994-12-16 EP EP03015590A patent/EP1366771B1/de not_active Revoked
- 1994-12-16 DE DE69435194T patent/DE69435194D1/de not_active Expired - Lifetime
- 1994-12-16 EP EP05018368A patent/EP1598077B1/de not_active Expired - Lifetime
- 1994-12-16 ES ES01118792T patent/ES2319860T3/es not_active Expired - Lifetime
- 1994-12-16 ES ES04019047T patent/ES2247575T3/es not_active Expired - Lifetime
- 1994-12-16 EP EP07002714A patent/EP1790352B1/de not_active Expired - Lifetime
- 1994-12-16 ES ES05018368T patent/ES2334357T3/es not_active Expired - Lifetime
- 1994-12-16 JP JP51812795A patent/JP3238154B2/ja not_active Expired - Lifetime
- 1994-12-16 EP EP99203735A patent/EP1010431B2/de not_active Expired - Lifetime
- 1994-12-16 ES ES99203735T patent/ES2237033T5/es not_active Expired - Lifetime
- 1994-12-16 DE DE122008000042C patent/DE122008000042I1/de active Pending
- 1994-12-16 EP EP00203421A patent/EP1103267B1/de not_active Revoked
- 1994-12-16 ES ES04019046T patent/ES2332905T3/es not_active Expired - Lifetime
- 1994-12-16 ES ES03015589T patent/ES2242126T3/es not_active Expired - Lifetime
- 1994-12-16 ES ES05018367T patent/ES2339865T3/es not_active Expired - Lifetime
- 1994-12-16 DE DE69433394T patent/DE69433394T3/de not_active Expired - Lifetime
- 1994-12-16 DE DE69435330T patent/DE69435330D1/de not_active Expired - Lifetime
- 1994-12-16 ES ES08017803T patent/ES2347384T3/es not_active Expired - Lifetime
- 1994-12-16 WO PCT/US1994/014717 patent/WO1995017904A2/en active IP Right Grant
- 1994-12-16 DE DE69434008T patent/DE69434008T2/de not_active Expired - Lifetime
- 1994-12-16 ES ES00203421T patent/ES2223393T3/es not_active Expired - Lifetime
- 1994-12-16 DE DE69434610T patent/DE69434610T2/de not_active Expired - Lifetime
- 1994-12-16 DE DE69427869T patent/DE69427869T2/de not_active Expired - Lifetime
-
2001
- 2001-06-11 HK HK01103981A patent/HK1033274A1/xx not_active IP Right Cessation
- 2001-07-16 JP JP2001214888A patent/JP2002068989A/ja not_active Withdrawn
- 2001-07-16 JP JP2001214889A patent/JP2002087987A/ja active Pending
- 2001-07-16 JP JP2001214884A patent/JP2002087984A/ja active Pending
- 2001-07-16 JP JP2001214890A patent/JP2002087988A/ja active Pending
- 2001-07-16 JP JP2001214883A patent/JP2002114706A/ja not_active Withdrawn
- 2001-07-16 JP JP2001214891A patent/JP2002097156A/ja not_active Withdrawn
- 2001-07-16 JP JP2001214886A patent/JP2002087985A/ja active Pending
- 2001-07-16 JP JP2001214887A patent/JP2002087986A/ja not_active Withdrawn
- 2001-07-16 JP JP2001214885A patent/JP2002097145A/ja active Pending
- 2001-07-16 JP JP2001214882A patent/JP2002104991A/ja not_active Withdrawn
- 2001-07-16 JP JP2001214881A patent/JP2002104990A/ja active Pending
-
2004
- 2004-09-28 HK HK04107484.4A patent/HK1064599A1/xx not_active IP Right Cessation
-
2005
- 2005-04-28 HK HK05103646A patent/HK1070831A1/xx not_active IP Right Cessation
- 2005-05-10 HK HK05103928A patent/HK1071071A1/xx not_active IP Right Cessation
- 2005-06-20 HK HK05105116.3A patent/HK1072375A1/xx not_active IP Right Cessation
-
2006
- 2006-01-26 JP JP2006017860A patent/JP2006160756A/ja not_active Withdrawn
- 2006-01-26 JP JP2006017858A patent/JP2006160754A/ja not_active Withdrawn
- 2006-01-26 JP JP2006017859A patent/JP2006160755A/ja not_active Withdrawn
- 2006-01-26 JP JP2006017857A patent/JP2006160753A/ja not_active Withdrawn
-
2007
- 2007-06-13 JP JP2007156168A patent/JP2007262086A/ja not_active Withdrawn
- 2007-09-26 JP JP2007248736A patent/JP2008056682A/ja not_active Withdrawn
- 2007-09-26 JP JP2007248739A patent/JP2008037877A/ja not_active Withdrawn
- 2007-09-26 JP JP2007248742A patent/JP2008056683A/ja not_active Withdrawn
- 2007-09-26 JP JP2007248745A patent/JP2008031176A/ja not_active Withdrawn
- 2007-10-26 JP JP2007278365A patent/JP2008063339A/ja not_active Withdrawn
- 2007-11-14 HK HK07112425A patent/HK1106700A1/xx not_active IP Right Cessation
-
2008
- 2008-08-27 FR FR08C0034C patent/FR08C0034I1/fr active Active
-
2010
- 2010-05-19 JP JP2010115462A patent/JP2010202659A/ja not_active Withdrawn
- 2010-05-19 JP JP2010115469A patent/JP2010202660A/ja not_active Withdrawn
- 2010-05-19 JP JP2010115472A patent/JP2010202661A/ja not_active Withdrawn
- 2010-05-19 JP JP2010115454A patent/JP2010209105A/ja not_active Withdrawn
-
2012
- 2012-05-10 JP JP2012108656A patent/JP2012188433A/ja active Pending
- 2012-05-10 JP JP2012108662A patent/JP2012167117A/ja active Pending
- 2012-05-10 JP JP2012108652A patent/JP2012167115A/ja active Pending
- 2012-05-10 JP JP2012108658A patent/JP2012167116A/ja active Pending
- 2012-05-10 JP JP2012108649A patent/JP2012167114A/ja active Pending
- 2012-05-23 JP JP2012117085A patent/JP2012197287A/ja active Pending
- 2012-09-10 JP JP2012198070A patent/JP2013006865A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69434540D1 (de) | Neurotoxisches Komponente von Botulinumtoxinen zur Behandlung von zervikaler Dystonie | |
DE69432299D1 (de) | Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen | |
DE122009000012I1 (de) | Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen. | |
DE69318693D1 (de) | Magnetischer Konditionierer zur Behandlung von Flüssigkeiten | |
DE69412552D1 (de) | Medizinisches Instrument zur Behandlung von Sinusitis | |
DE69319270D1 (de) | Verfahren zur Behandlung von organischen Schlämmen | |
ITRM940150A0 (it) | Procedimento per il trattamento di acque di scarico fortemente colorate. | |
DE3856398D1 (de) | Verfahren zur Behandlung von Gleitkörpern | |
DE59403655D1 (de) | Vorrichtung zur oberflächenbehandlung von fahrzeugkarosserien | |
DE69404785D1 (de) | Vorrichtung zur Behandlung von Oberflächen | |
DE3884200D1 (de) | Verfahren zur Behandlung von Mastitis und anderen Staphylokokkeninfektionen. | |
DE69422842D1 (de) | Verfahren und Einrichtung zur Behandlung von Lithium | |
DE69421196D1 (de) | Vorrichtung zur behandlung von überbiss | |
DE59600709D1 (de) | Adsorbens zur behandlung von ölen und/oder fetten | |
DE69423131D1 (de) | Verfahren zur Behandlung von Mycobakterien enthaltenden Auswürfen | |
DE69405711D1 (de) | Behandlung von rueckstandsoel | |
DE69834937D1 (de) | Antibiotika zur behandlung von magengeschwuren | |
DE69701458D1 (de) | Verwendung von buckminsterfulleren zur behandlung neurotoxischer verletzungen | |
DE69418931D1 (de) | Verwendung von VIP und deren Analogen und Fragmenten zur Behandlung von neurodegenerativen Krankheiten | |
DE69408394D1 (de) | 4-Piperidino-piperidin zur Behandlung von Tumoren | |
DE69412178D1 (de) | Apparat zur Behandlung von Lagen | |
DE69414793D1 (de) | Verfahren zur Behandlung von Kunststoffgläser | |
DE69107246D1 (de) | Einrichtung und Verfahren zur Verbesserung der Steuerung von Schaltnetzteilen. | |
DE69203707D1 (de) | Verfahren zur Reinigung von Fluorethanen und Chlorfluorethanen. | |
DE59305800D1 (de) | Werkzeug zur behandlung von oberflächen von bauteilen |